Ardelyx Q3 2025: product revenue $105.5M, IBSRELA +92% YoY, guidance raised

ARDELYX, INC.

2025-Q3 EPS reported -$0.25 revenue$282,105,000

Total Q3 product revenue $105.5M (+15% YoY); net loss $1.0M ($0.00 per share).
IBSRELA revenue $78.2M (+92% YoY, +20% QoQ); 2025 guidance raised to $270-275M.
XPHOZAH revenue $27.4M (+9% QoQ); YoY decline due to loss of Part D coverage.
Cash $242.7M; new NHE3 inhibitor RDX10531 with IND submission targeted for 2026.
Appointed Sue Hohenleitner as CFO effective Nov 4, plus new CMO and CTO in Q3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.